For years, people taking one of the world’s most common heart drugs have described the same nagging side effect: sore, aching ...

Shares of Eli Lilly LLY rose nearly 2% on Thursday after the company announced that a late-stage study evaluating its ...

Retatrutide is an investigational triple agonist developed by Eli Lilly that targets GLP-1, GIP and glucagon receptors, and early trials suggest very strong ...

Retatrutide, the next generation of GLP-1 drug from Eli Lilly, helped participants lose an average of 71.2 pounds and reduce ...

Pancreatic cancer is one of the deadliest malignancies, with survival rates remaining dismally low despite major advances in ...

Discusses ABS-201 Program and Clinical Approach for Androgenetic Alopecia December 11, 2025 10:00 AM ESTCompany ...

SAN ANTONIO -- The antibody-drug conjugate (ADC) sacituzumab govitecan (Trodelvy) failed to outperform chemotherapy as first ...

Stress affects many systems in our body and biologists Marcel Schaaf and Erin Faught at Radboud University are figuring out ...

Rezolute said on Thursday its therapy aimed at controlling excessive insulin activity in patients with a rare genetic disorder did not show significant benefit in a late-stage trial.

GLP-1 RAs probably have little or no effect on risk for thyroid cancer, pancreatic cancer, breast cancer, or kidney cancer.

New psychoactive substances, originally developed as potential analgesics but abandoned due to adverse side effects, may ...

Mapping how Narcan reverses opioid overdose can provide a molecular blueprint for developing more effective drugs against ...